Assessment of Energetic Resonance by Cutaneous Stimulation on Withdrawal Alcohol Symptoms.

Not Applicable

Completed

• Conditions: Alcohol Withdrawal Syndrome
• Interventions: Other: Energetic Resonance by Cutaneous Stimulation

• Registration Number: NCT02146716
• Lead Sponsor: Hospices Civils de Lyon

Brief Summary

The purpose of RESC study is to assess the efficacy of Energetic Resonance by Cutaneous Stimulation on alcohol withdrawal symptoms measured by CUSHMAN score and in a second time to measure the benzodiazepine amount prescribed during the withdrawal time.

Detailed Description

Not available

Study Timeline

• Study Start: 2014-05
• Study First Submitted: 2014-05-19
• Study First Submitted QC: 2014-05-21
• Study First Posted: 2014-05-26
• Primary Completion: 2016-11
• Study Completion: 2017-02
• Status Verified: 2017-08
• Last Update Submitted: 2017-08-22
• Last Update Posted: 2017-08-23

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 43

Inclusion Criteria

• Men and women between 18 and 80 years,
• Patient with alcohol addiction,
• Patient needing alcohol withdrawal in a hospital.
• Patient with social Security,
• Patient with inform consent signed.

Exclusion Criteria

• Pregnant women
• Minor.
• Major with guardianship.
• People without sufficient information because of troubles of cognitive functions, or without sufficient knowledge of French language.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Energetic Resonance by Cutaneous Stimulation	Energetic Resonance by Cutaneous Stimulation	Energetic Resonance by Cutaneous Stimulation session in addition to standard treatment for patients with withdrawal alcohol symptoms.

Primary Outcome Measures

Name	Time	Method
Cushman Score measure after Energetic Resonance by Cutaneous Stimulation	daily during one week	CUSHMAN score is represented by a scale with 7 variables collecting physiological modifications or behavioural manifestations related to adrenergic answer, neurovegetative signs, confusion, nervousness, perceptive or hallucinatory phenomena.

Secondary Outcome Measures

Name	Time	Method
Quality of life scale	day 0
Anxiety depression scale	pre-screening, day 3 and day 7
Analogic Visual Scale	before and after each Energetic Resonance by Cutaneous Stimulationsession at day 2, day 4 and day 6.
prescribed benzodiazepine amount	day 0 to day 7

Trial Locations

Locations (1)

Hôpital croix rousse; 🇫🇷 Lyon, France